PL1690549T3 - Środek immunoterapeutyczny do stosowania w połączeniu z innymi lekami do skojarzonego leczenia gruźlicy - Google Patents

Środek immunoterapeutyczny do stosowania w połączeniu z innymi lekami do skojarzonego leczenia gruźlicy

Info

Publication number
PL1690549T3
PL1690549T3 PL04791401T PL04791401T PL1690549T3 PL 1690549 T3 PL1690549 T3 PL 1690549T3 PL 04791401 T PL04791401 T PL 04791401T PL 04791401 T PL04791401 T PL 04791401T PL 1690549 T3 PL1690549 T3 PL 1690549T3
Authority
PL
Poland
Prior art keywords
agent
combined treatment
immunotherapic
pharmaceuticals
tuberculosis
Prior art date
Application number
PL04791401T
Other languages
English (en)
Inventor
Iglesias Pere Joan Cardona
Riera Isabel Amat
Original Assignee
Archivel Farma Sl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Archivel Farma Sl filed Critical Archivel Farma Sl
Publication of PL1690549T3 publication Critical patent/PL1690549T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
PL04791401T 2003-10-31 2004-10-29 Środek immunoterapeutyczny do stosowania w połączeniu z innymi lekami do skojarzonego leczenia gruźlicy PL1690549T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ES200302551A ES2231037B1 (es) 2003-10-31 2003-10-31 Agente inmunoterapico util para el tratamiento combinado de la tuberculosis en asociacion con otros farmacos.
PCT/ES2004/000482 WO2005042013A1 (es) 2003-10-31 2004-10-29 Agente immunoterápico útil para el tratamento combinado de la tuberculosis en associación con otros fármacos
EP04791401A EP1690549B1 (en) 2003-10-31 2004-10-29 Immunotherapic agent which is used for the combined treatment of tuberculosis together with other pharmaceuticals

Publications (1)

Publication Number Publication Date
PL1690549T3 true PL1690549T3 (pl) 2010-01-29

Family

ID=34530979

Family Applications (1)

Application Number Title Priority Date Filing Date
PL04791401T PL1690549T3 (pl) 2003-10-31 2004-10-29 Środek immunoterapeutyczny do stosowania w połączeniu z innymi lekami do skojarzonego leczenia gruźlicy

Country Status (20)

Country Link
US (1) US8246944B2 (pl)
EP (1) EP1690549B1 (pl)
JP (1) JP4998988B2 (pl)
KR (1) KR101146469B1 (pl)
CN (1) CN100490894C (pl)
AT (1) ATE428442T1 (pl)
AU (1) AU2004285305B2 (pl)
BR (1) BRPI0415695B8 (pl)
CA (1) CA2543659C (pl)
DE (1) DE602004020663D1 (pl)
DK (1) DK1690549T3 (pl)
ES (2) ES2231037B1 (pl)
IL (1) IL175030A (pl)
MA (1) MA28121A1 (pl)
NZ (1) NZ546715A (pl)
PL (1) PL1690549T3 (pl)
PT (1) PT1690549E (pl)
RU (1) RU2341287C2 (pl)
WO (1) WO2005042013A1 (pl)
ZA (1) ZA200604234B (pl)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2231037B1 (es) 2003-10-31 2005-12-16 Archivel Technologies, Sl Agente inmunoterapico util para el tratamiento combinado de la tuberculosis en asociacion con otros farmacos.
US20100166840A1 (en) * 2006-05-12 2010-07-01 Japan Bcg Laboratory Liposome having lipid membrane containing bacterial cell component
ES2307402B1 (es) * 2006-10-30 2009-09-30 Archivel Farma, S.L. Vacuna profilactica contra la tuberculosis.
ES2335177B1 (es) * 2008-09-19 2011-02-28 Archivel Farma, S.L. Agente inmunoterapeutico apropiado para la profilaxis primaria de la tuberculosis.
EP2471511A1 (en) 2011-01-04 2012-07-04 Archivel Farma, SL Liposome formulation suitable for treating or preventing tuberculosis
WO2012093137A1 (en) * 2011-01-04 2012-07-12 Archivel Farma, Sl Liposome formulation suitable for treating or preventing tuberculosis
PL2802345T3 (pl) 2012-01-12 2018-08-31 Archivel Farma, S.L. Szczepionka mtb-c przeciw reakcjom alergicznym
ES2758400B2 (es) 2018-11-02 2021-01-20 Univ Granada Nanoparticulas biomimeticas mediadas por mamc
WO2023062066A1 (en) 2021-10-14 2023-04-20 Archivel Farma, S.L. Liposome formulations for treatment of active tuberculosis
WO2025191183A1 (en) 2024-03-15 2025-09-18 Archivel Farma S.L. Liposome formulations for the treatment of cancer

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3125598A1 (de) * 1981-06-30 1983-01-13 Mahle Gmbh, 7000 Stuttgart Einrichtung zur druckbeaufschlagung des presszylinders einer druckgiessmaschine
JPS59161320A (ja) * 1983-03-04 1984-09-12 Maruyama Chisato リポ多糖体およびその製造法
GB8404280D0 (en) * 1984-02-17 1984-03-21 Stanford J L Biological preparations
JPS624701A (ja) * 1985-06-29 1987-01-10 Maruyama Chisato リポ多糖体及びその製造法
US4744984A (en) * 1985-10-08 1988-05-17 Vetrepharm Research, Inc. Antiviral immunotherapeutic agent and preparation thereof
US5542935A (en) * 1989-12-22 1996-08-06 Imarx Pharmaceutical Corp. Therapeutic delivery systems related applications
US6641814B1 (en) * 1997-04-02 2003-11-04 Statens Serum Institut Nucleic acids fragments and polypeptide fragments derived from M. tuberculosis
US5785975A (en) * 1995-06-26 1998-07-28 Research Triangle Pharmaceuticals Adjuvant compositions and vaccine formulations comprising same
US6284255B1 (en) * 1996-08-29 2001-09-04 Genesis Research & Development Corporation Limited Compounds and methods for treatment and diagnosis of mycobacterial infections
US6982085B2 (en) * 1997-04-02 2006-01-03 Statens Serum Institut TB diagnostic based on antigens from M. tuberculosis
EP1117683A2 (en) * 1998-10-08 2001-07-25 Statens Serum Institut Tb vaccine and diagnostic based on antigens from the m. tuberculosis cell
RU2153354C1 (ru) * 1999-03-31 2000-07-27 Московский городской научно-практический центр борьбы с туберкулезом Вакцина против туберкулеза
WO2002045736A1 (en) * 2000-12-08 2002-06-13 The Johns Hopkins University Methods for improved diagnosis and treatment of mycobacterial infections
EP1360498B1 (en) * 2001-01-08 2009-10-14 The Government of the United States of America, as represented by the Secretary, Department of Health & Human Services Latent human tuberculosis diagnostic antigen and method of use
AU2002254206A1 (en) * 2001-03-16 2002-10-03 Sarawak Medichem Pharmaceuticals, Inc. Pyranocoumarin compounds as a novel pharmacophore with anti-tb activity
EP2196473A1 (en) 2001-07-04 2010-06-16 Health Protection Agency Mycobacterial antigens expressed during latency
WO2003018053A1 (en) 2001-08-22 2003-03-06 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Vaccine against mycobacterial-induced diseases
EP1478391A1 (en) 2002-01-29 2004-11-24 Bakulesh Mafatlal Khamar Method of providing prophylaxis for tuberculosis in hiv positive individuals
ES2231037B1 (es) 2003-10-31 2005-12-16 Archivel Technologies, Sl Agente inmunoterapico util para el tratamiento combinado de la tuberculosis en asociacion con otros farmacos.
DE102004053141A1 (de) * 2004-11-03 2006-05-04 Schülke & Mayr GmbH Desinfektionsmittel mit verbesserter Wirksamkeit gegen Mykobakterien

Also Published As

Publication number Publication date
CN1874785A (zh) 2006-12-06
ZA200604234B (en) 2007-11-28
CA2543659A1 (en) 2005-05-12
IL175030A (en) 2012-02-29
CN100490894C (zh) 2009-05-27
JP2007509910A (ja) 2007-04-19
US8246944B2 (en) 2012-08-21
ATE428442T1 (de) 2009-05-15
HK1098362A1 (zh) 2007-07-20
MA28121A1 (fr) 2006-08-01
BRPI0415695B1 (pt) 2019-09-10
US20070269501A1 (en) 2007-11-22
AU2004285305B2 (en) 2009-11-12
ES2231037B1 (es) 2005-12-16
DE602004020663D1 (de) 2009-05-28
EP1690549B1 (en) 2009-04-15
DK1690549T3 (da) 2009-08-17
IL175030A0 (en) 2006-08-20
RU2341287C2 (ru) 2008-12-20
EP1690549A1 (en) 2006-08-16
ES2231037A1 (es) 2005-05-01
JP4998988B2 (ja) 2012-08-15
RU2006118795A (ru) 2007-12-10
PT1690549E (pt) 2009-07-20
CA2543659C (en) 2012-04-17
NZ546715A (en) 2008-05-30
KR101146469B1 (ko) 2012-05-21
AU2004285305A1 (en) 2005-05-12
BRPI0415695A (pt) 2006-12-26
KR20060126963A (ko) 2006-12-11
ES2325835T3 (es) 2009-09-21
WO2005042013A1 (es) 2005-05-12
BRPI0415695A8 (pt) 2019-01-15
BRPI0415695B8 (pt) 2021-05-25

Similar Documents

Publication Publication Date Title
TW200508214A (en) Novel compounds
WO2004110375A3 (en) Combination therapy for the treatment of diabetes
YU20050003A (sh) Postupak i uređaj za davanje co
WO2004073623A3 (en) Treatment of conditions associated with decreased nitric oxide bioavailability, including elevated arginase conditions
EP1611880A3 (en) Pharmaceutical formulations for the safe administration of drugs used in the treatment of drug addiction
AU2003216820A1 (en) Use of microfabricated devices for radiosynthesis
IL171683A (en) Immunosuppressive Compounds, Medicinal Products Containing Them and Their Use in the Preparation of Medication for Treatment
ATE342053T1 (de) Formulierungen zur inhalation
IL175030A0 (en) Immunotherapic agent which is used for the combined treatment of tuberculosis together with other pharmaceuticals
SG167657A1 (en) Novel medicament compositions based on tiotropium salts and on salmeterol salts
EP1071451A4 (en) COMPOUNDS AND METHODS FOR IMMUNOTHERAPY AND DIAGNOSIS OF TUBERCULOSIS
WO2004043341A3 (en) Treatment for hemorrhagic shock
BRPI0408655A (pt) formulações compreendendo um agente ativo e cacau em pó e a sua utilização
PL372457A1 (pl) Nowe kompozycje farmaceutyczne zawierające polimorf A flibanseryny
WO2003087049A3 (de) Arzneimittelkombinationen enthaltend heterocyclische verbindungen und ein neues anticholinergikum
MY134167A (en) Biphenylcarboxamides useful as lipid lowering agents
WO2004014367A3 (en) Use of an amyloid beta vaccination in combination with a selective cox-2 inhibitor for the treatment of alzheimer's disease
WO2003039592A3 (de) Zelluläre impfstoffe mit adjuvanzien
GR20020100478A (el) Ανυδρη κρυσταλλικη μορφη της βαλακyκλοβιρης υδροχλωρικης
WO2004073615A8 (en) Deazaflavin compounds and methods of use thereof
PL371784A1 (pl) Pentafluorotio-benzoiloguanidyny, sposób ich wytwarzania, ich zastosowanie jako środka leczniczego lub diagnostycznego oraz środek leczniczy zawierający te związki
TW200511999A (en) Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and parathyroid hormone
WO2000055194A3 (en) Tuberculosis antigens and methods of use therefor
WO2004110373A3 (en) Therapeutic vaccine compositions for the treatment of type 1 diabetes
UA90504C2 (ru) Лекарственное средство для лечения заболеваний дыхательных путей